Running a IMNM wheel strategy lets you generate consistent premium income on Immunome Inc while setting your own entry and exit prices on the underlying. Immunome Inc's wheel combines cash-secured puts and covered calls into a repeatable cycle: sell puts at strikes where you'd be happy to own IMNM, and if assigned, sell calls at strikes where you'd be happy to sell. Use our scanner to find the best IMNM wheel strategy setups in real time.
The wheel works best on liquid, high-quality names with stable fundamentals and active options markets — exactly the profile many large-cap leaders fit. The mechanics are simple: sell a cash-secured put on IMNM, collect premium, and either keep the premium if it expires worthless or take assignment at a discount to current price. Once assigned, sell covered calls against the shares to keep collecting premium until they're called away. Choosing the right strikes, expirations, and IV environment is what separates a profitable IMNM wheel from a losing one.
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
The difference between a wheel that compounds and one that bleeds comes down to strike selection, IV timing, and discipline on assignment. Our scanner handles the heavy lifting: it ranks every leg of the IMNM wheel strategy by delta, premium yield, IV rank, and days to expiration, so you can deploy capital where the math works. Build your IMNM wheel strategy on data, not gut feel — and let the options wheel do what it does best: pay you to wait.
